Paul Beckett
Family Medicine · Blackfoot, IDNPI 1831115757
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (41.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Eli Lilly at 44.1% of the total. Reporting peaked in 2019 at $4,746 and has fallen 81.5% since, to $877 in 2025. Among family medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $44.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$7K
- Pfizer$3K
- Novo Nordisk AS$2K
- AbbVie$1K
- Novo Nordisk$658
- Lilly USA, LLC$440
- plus $3K from 33 others
Across 251 payments — averaging $1314.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$221K
- GSK$54K
- Janssen Research & Development, LLC$28K
- Pfizer$25K
- Sanofi Pasteur Inc.$3K
What the payments were for
- Consulting fees$2,87517%
- Travel & lodging$7,01741%
- Food & beverage$6,89441%
- Education$1811%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 32 | $7,482 |
| Pfizer | 35 | $2,671 |
| Novo Nordisk AS | 4 | $1,708 |
| AbbVie(2 entities) | 70 | $1,248 |
| Novo Nordisk | 33 | $658 |
| Lilly USA, LLC | 38 | $440 |
| Amgen | 27 | $331 |
| Astellas Pharma US Inc | 16 | $254 |
| Phathom Pharmaceuticals, Inc. | 9 | $239 |
| Insulet Corporation | 12 | $223 |
| Abbott | 13 | $195 |
| Otsuka America Pharmaceutical, Inc. | 8 | $160 |
| Johnson & Johnson | 11 | $157 |
| Boehringer Ingelheim | 9 | $140 |
| Novartis | 7 | $122 |
| GSK | 8 | $105 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $92 |
| AstraZeneca | 6 | $77 |
| Merck | 4 | $64 |
| Lundbeck LLC | 3 | $60 |
| Bayer | 3 | $53 |
| Boston Scientific | 3 | $45 |
| Medtronic(2 entities) | 3 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Amarin Pharma, Inc. | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 3 | $37 |
| Alkermes, Inc. | 1 | $32 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Bristol Myers Squibb | 2 | $29 |
| Tandem Diabetes Care, Inc. | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $17 |
| Dexcom, Inc. | 1 | $16 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,967 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 119 | $118,287 |
| EliquisApixaban | 80 | $69,851 |
| OzempicSemaglutide | 72 | $69,208 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 49 | $55,219 |
| MounjaroTirzepatide | 56 | $55,155 |
| GlyxambiEmpagliflozin/Linagliptin | 33 | $41,435 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 21 | $32,254 |
| Humulin R U-500Insulin Regular, Human | 11 | $31,329 |
| TrulicityDulaglutide | 25 | $30,306 |
| FarxigaDapagliflozin Propanediol | 28 | $27,172 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $23,897 |
| MyrbetriqMirabegron | 42 | $22,046 |
| RexultiBrexpiprazole | 12 | $16,139 |
| MultaqDronedarone Hcl | 11 | $8,408 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $8,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $140 | $214,941201 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $658 | $101,46293 claims |
| Lilly USA, LLCMounjaro, Trulicity | $440 | $85,46081 claims |
| PfizerEliquis | $2,671 | $69,85180 claims |
| AstraZenecaFarxiga | $77 | $27,17228 claims |
| Astellas Pharma US IncMyrbetriq | $254 | $22,04642 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $160 | $16,13912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.
Other family medicine in Blackfoot
- Gary SoucieBlackfoot$37K
- Matthew FackrellBlackfoot$5K
- Kenneth CongerSandpoint$266K
- David ButukMeridian$206K
- Anne BroadwayIdaho Falls$184K
- Timothy McHughMeridian$165K
- Phyllis YouBoise$88K
- Ralph SutherlinSt Maries$73K
- Henry DownsCoeur D Alene$69K
- Crystal PyrakCoeur D Alene$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.